Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Dermata Therapeutics stock
Learn how to easily invest in Dermata Therapeutics stock.
Dermata Therapeutics is a biotechnology business based in the US. Dermata Therapeutics shares (DRMA) are listed on the NASDAQ and all prices are listed in US Dollars. Dermata Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Dermata Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – DRMA. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Dermata Therapeutics stock price (NASDAQ: DRMA)Use our graph to track the performance of DRMA stocks over time.
Dermata Therapeutics shares at a glance
|Latest market close||$0.27|
|52-week range||$0.16 - $2.45|
|50-day moving average||$0.37|
|200-day moving average||$0.63|
|Wall St. target price||$6.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.85|
Buy Dermata Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Dermata Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Dermata Therapeutics price performance over time
|1 week (2023-01-26)||-4.23%|
|1 month (2022-12-30)||-33.03%|
|3 months (2022-11-02)||-57.86%|
|6 months (2022-08-02)||-48.99%|
|1 year (2022-02-02)||-87.66%|
|2 years (2021-02-02)||-99.45%|
|3 years (2020-01-31)||50|
|5 years (2018-02-02)||50|
Dermata Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-58.01%|
|Return on equity TTM||-105.15%|
|Market capitalisation||$3.5 million|
TTM: trailing 12 months
Dermata Therapeutics share dividends
We're not expecting Dermata Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Johnson-and-Johnson (JNJ.US) (2.69% forward annual dividend yield)
Dermata Therapeutics overview
Dermata Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. .
Frequently asked questionsWhat percentage of Dermata Therapeutics is owned by insiders or institutions?
Currently 32.565% of Dermata Therapeutics shares are held by insiders and 1.601% by institutions. How many people work for Dermata Therapeutics?
Latest data suggests 8 work at Dermata Therapeutics. When does the fiscal year end for Dermata Therapeutics?
Dermata Therapeutics's fiscal year ends in December. Where is Dermata Therapeutics based?
Dermata Therapeutics's address is: 3525 Del Mar Heights Road, San Diego, CA, United States, 92130 What is Dermata Therapeutics's ISIN number?
Dermata Therapeutics's international securities identification number is: US2498451085
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert